Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported multiple agreements and transactions in a recent Form 8-K filing with the SEC. On August 15, 2024, the company entered into a Consulting Agreement with Veritas Consulting Group, Inc. for investor relations and business advisory services, issuing 150,000 shares of restricted common stock and agreeing to a monthly cash payment of $7,500. Subsequently, on August 22, Mangoceuticals signed a Marketing Agreement with Levo Healthcare Consulting, Inc., issuing 195,000 shares of restricted common stock and agreeing to a monthly cash payment of $6,250, along with potential warrants based on customer milestones. On September 10, the company engaged Luca Consulting, LLC for management and consulting services, issuing 650,000 shares of restricted common stock and agreeing to a cash payment schedule totaling $30,000. Additionally...Show More

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported multiple agreements and transactions in a recent Form 8-K filing with the SEC. On August 15, 2024, the company entered into a Consulting Agreement with Veritas Consulting Group, Inc. for investor relations and business advisory services, issuing 150,000 shares of restricted common stock and agreeing to a monthly cash payment of $7,500. Subsequently, on August 22, Mangoceuticals signed a Marketing Agreement with Levo Healthcare Consulting, Inc., issuing 195,000 shares of restricted common stock and agreeing to a monthly cash payment of $6,250, along with potential warrants based on customer milestones. On September 10, the company engaged Luca Consulting, LLC for management and consulting services, issuing 650,000 shares of restricted common stock and agreeing to a cash payment schedule totaling $30,000. Additionally, Mangoceuticals disclosed an Equity Line of Credit (ELOC) agreement with Platinum Point Capital, dated April 5, 2024, for up to $25 million in common stock purchases. Under this agreement, the company sold 2,000,000 shares of common stock to the purchaser for a net amount of $521,016 on October 1, 2024. The company also reported conversions of Series B Preferred Stock by Platinum Point Capital into common stock on September 26 and October 2, 2024, totaling 1,722,394 shares. All securities transactions were exempt from registration under the Securities Act, with the resale of shares issued under the ELOC and upon conversion of Series B Preferred Stock registered with the SEC.